Cogent Biosciences (COGT) Stock Overview
A biotechnology company, focuses on developing precision therapies for genetically defined diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
COGT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Cogent Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.09 |
| 52 Week High | US$17.15 |
| 52 Week Low | US$3.72 |
| Beta | 0.30 |
| 1 Month Change | 13.63% |
| 3 Month Change | 39.55% |
| 1 Year Change | 34.08% |
| 3 Year Change | 25.51% |
| 5 Year Change | 48.98% |
| Change since IPO | 68.31% |
Recent News & Updates
Recent updates
Cogent Biosciences: Moving Forward
Aug 26Will Cogent Biosciences (NASDAQ:COGT) Spend Its Cash Wisely?
Apr 03
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
Jan 18Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Dec 18Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Sep 04Cogent Biosciences: Inflection Year Directly Ahead
Jun 23Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Shareholder Returns
| COGT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.5% | -0.8% | 2.0% |
| 1Y | 34.1% | 2.9% | 18.7% |
Return vs Industry: COGT exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: COGT exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| COGT volatility | |
|---|---|
| COGT Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COGT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: COGT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 205 | Andy Robbins | www.cogentbio.com |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma.
Cogent Biosciences, Inc. Fundamentals Summary
| COGT fundamental statistics | |
|---|---|
| Market cap | US$2.26b |
| Earnings (TTM) | -US$284.08m |
| Revenue (TTM) | n/a |
Is COGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COGT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$284.08m |
| Earnings | -US$284.08m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 28.3% |
How did COGT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 21:46 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cogent Biosciences, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Joel Beatty | Baird |
| David Lebowitz | Citigroup Inc |